Praxis Precision Medicines to Hold Virtual Investor Event to Discuss Clinical Programs in Developmental and Epileptic Encephalopathies

Rhea-AI Summary

Praxis Precision Medicines (NASDAQ: PRAX) has announced a virtual investor event scheduled for May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT. The webinar will focus on the company's clinical programs in developmental and epileptic encephalopathies (DEEs).

The presentation will cover three key clinical studies:

• The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
• The EMERALD study evaluating relutrigine for broader DEEs
• The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE

The event will be hosted by the Praxis management team, with a replay available on the company's website for 90 days under the 'Events & Presentations' page.

BOSTON, April 08, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be hosting a virtual investor event on Friday, May 2, 2025 from 10:00 a.m. to 11:30 a.m. EDT.

The webinar, hosted by the Praxis management team, will focus on the company’s clinical programs in developmental and epileptic encephalopathies (DEEs) including:

• The EMBOLD study evaluating relutrigine for SCN2A and SCN8A DEEs
• The EMERALD study evaluating relutrigine for broader DEEs
• The EMBRAVE3 study evaluating elsunersen for SCN2A gain-of-function DEE
  

To RSVP and attend the live event, you may click here.   A replay of the webinar will also be available through the “Events & Presentations” page under the “Investors + Media” section of the company’s website for 90 days.

About Praxis 
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.

Investor Contact:
Praxis Precision Medicines
investors@praxismedicines.com
857-702-9452

Media Contact:
Dan Ferry
Life Science Advisors
Daniel@lifesciadvisors.com
617-430-7576

FAQ

What clinical trials will be discussed at Praxis Precision Medicines' May 2025 investor event?

The event will discuss three trials: EMBOLD (relutrigine for SCN2A/SCN8A DEEs), EMERALD (relutrigine for broader DEEs), and EMBRAVE3 (elsunersen for SCN2A gain-of-function DEE).

When is Praxis Precision Medicines (PRAX) hosting its virtual investor event for DEE programs?

The virtual investor event is scheduled for Friday, May 2, 2025, from 10:00 a.m. to 11:30 a.m. EDT.

How long will the replay of Praxis Precision Medicines' May 2025 investor event be available?

The webinar replay will be available for 90 days through the 'Events & Presentations' page on the company's website.

What therapeutic candidates is PRAX developing for developmental and epileptic encephalopathies?

PRAX is developing two therapeutic candidates: relutrigine (for SCN2A, SCN8A, and broader DEEs) and elsunersen (for SCN2A gain-of-function DEE).